Overview

To Evaluate the Efficacy of AL-38583 in the Reduction of Tear Eosinophil Count Following Conjunctival Allergen Challenge

Status:
Withdrawn
Trial end date:
2009-05-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of the study is to determine whether Al38583 Ophthalmic Solution is safe and effective in reducing tear eosinophil levels at 5-8 hours after Conjunctival Allergen Challenge (CAC).
Phase:
Phase 2
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Alcon Research
Treatments:
Dexamethasone
Ophthalmic Solutions
Criteria
Inclusion Criteria:

- Have a positive bilateral CAC reaction (>2 itching and > conjunctival redness) to cat
hair, cat dander, dust mites, cockroaches and/or dog dander within 10 minutes of
instillation of the last titration of allergen at Visit 1

Exclusion Criteria:

- Have a known allergy to the study medication(s) or their components (ex.,
dexamethasone, benzalkonium chloride)